Safety, Efficacy and Acute Angiographic Outcome of the New Everolimus Eluting Stent with Correlation to Short-Term Clinical Follow-up in Patient with Acute Coronary Syndrome
SOLIMAN GHARIB, M.D., M., HOSSAM ELHOSSARY, M.D., M. (2021). Safety, Efficacy and Acute Angiographic Outcome of the New Everolimus Eluting Stent with Correlation to Short-Term Clinical Follow-up in Patient with Acute Coronary Syndrome. EKB Journal Management System, 89(June), 967-974. doi: 10.21608/mjcu.2021.184525
MOHAMED IMAM, M.D.; SOLIMAN GHARIB, M.D.; MOHAMED ABDELGHANY, M.D.; HOSSAM ELHOSSARY, M.D.. "Safety, Efficacy and Acute Angiographic Outcome of the New Everolimus Eluting Stent with Correlation to Short-Term Clinical Follow-up in Patient with Acute Coronary Syndrome". EKB Journal Management System, 89, June, 2021, 967-974. doi: 10.21608/mjcu.2021.184525
SOLIMAN GHARIB, M.D., M., HOSSAM ELHOSSARY, M.D., M. (2021). 'Safety, Efficacy and Acute Angiographic Outcome of the New Everolimus Eluting Stent with Correlation to Short-Term Clinical Follow-up in Patient with Acute Coronary Syndrome', EKB Journal Management System, 89(June), pp. 967-974. doi: 10.21608/mjcu.2021.184525
SOLIMAN GHARIB, M.D., M., HOSSAM ELHOSSARY, M.D., M. Safety, Efficacy and Acute Angiographic Outcome of the New Everolimus Eluting Stent with Correlation to Short-Term Clinical Follow-up in Patient with Acute Coronary Syndrome. EKB Journal Management System, 2021; 89(June): 967-974. doi: 10.21608/mjcu.2021.184525

Safety, Efficacy and Acute Angiographic Outcome of the New Everolimus Eluting Stent with Correlation to Short-Term Clinical Follow-up in Patient with Acute Coronary Syndrome

The Medical Journal of Cairo University
Article 65, Volume 89, June, June 2021, Page 967-974  XML PDF (254.62 K)
DOI: 10.21608/mjcu.2021.184525
View on SCiNiTO View on SCiNiTO
Authors
MOHAMED IMAM, M.D.; SOLIMAN GHARIB, M.D.; MOHAMED ABDELGHANY, M.D.; HOSSAM ELHOSSARY, M.D.
The Department of Cardiology, Faculty of Medicine, Cairo University* and National Heart Institute (NHI) **, Giza, Egypt
Abstract
Abstract Background: Drug-eluting stents are used in 80%. To 90% of revascularization procedures in the United States. Everolimus embedded in a durable polymer on a cobalt chromium Stent has shown superiority compared with Bare Metal Stents (BMS), and paclitaxel eluting stent for reduction of both late loss and binary restenosis. Aim of Study: To study the safety, efficacy and acute angiographic outcome of the new Everolimus Eluting Stent in correlation with short-term clinical follow-up in patient with Acute Coronary Syndrome (ACS). Patients and Methods: A prospective study in which ninety-five patients with (ACS), Scheduled for PCI in the cardiac catheterization laboratory in Cairo University Hospitals or NHI, using Everolimus DES, were enrolled from Jan. 2009 to June 2009. Their clinical, angiographic, interventional and follow-up data were collected and analyzed. Results: Acute success was achieved in all the cases with no device failure, after six month of follow-up, patients (94.5%) had expressed no events or chest pain, 1 patient had stable angina and refused to redo the coronary angiography, 3 patients had redo the coronary angiography due to recurrent chest pain (two of them had redo PCI in remote vessel and the other had no significant lesion), and 1 patient died because of retroperitoneal hematoma. Conclusion: The everolimus eluting stent are a safe type of drug eluting stent in clinical Practice with favorable short term outcomes in patients with acute coronary syndromes.
Keywords
Everolimus eluting stent; Acute coronary syn-drome
Statistics
Article View: 78
PDF Download: 108